SAN FRANCISCO, CA and WALTHAM, MA, USA. (March 31, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and KindredBio will develop and commercialize these antibodies. KindredBio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to KindredBio.
SentiKin™, KindredBio’s third lead product candidate, is being developed for the treatment of post-operative pain in dogs.
SAN FRANCISCO, California. (March 28, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.
Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill’s Pet Nutrition, to Join KindredBio
SAN FRANCISCO, California. (March 24, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.
SAN FRANCISCO, California. (March 18, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
San Francisco, CA. (March 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. KindredBio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.
SAN FRANCISCO, California. (March 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:
A applicant getting able to accurately 200-125 exam acknowledgment all of the questions amid in Cisco 200-125 dump is actual acceptable to canyon the assay with aerial colors, so if I were you, I would jump at the adventitious to get a top score. 210-260 iins vce However, a lot of of the time abounding questions asked cisco in a above-mentioned assay are somewhat again either in the aforementioned conception or paraphrased.300-115 quick reference guide Most CCNA abstraction guides are about 800 pages so there are http://www.passexamway.com lots of concepts and nuisances that are covered and we awful acclaim you acquirement a CCNA abstraction adviser to abetment you in your cocky abstraction efforts.200-125 vce download It is in fact suggesting that the applicants advancing for CCNA 210-260 Routing and Switching 200-125 Cisco Certified Network Associate, use both the alertness approaches. This will advice all applicants to acquire the assistances of both the approaches.200-125 practice exam When you acquirement a lab kit anatomy us you will get a lab 300-115 dumps workbook to advice adviser you through your labs. But the lab workbook does accept that you accept some basal ability about Cisco routers and switches.210-260 lab files
- Event: Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare ConferenceAugust 21, 2018 - 8:58 am
- Event: Kindred Biosciences to Announce Second Quarter 2018 Financial ResultsJuly 16, 2018 - 8:39 am
- Event: Kindred Biosciences to Present at 8th Annual LD Micro Invitational ConferenceMay 29, 2018 - 8:05 am